Yanxiang Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yanxiang Sun has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Li Feng
Department of Cardiology, Zhongshan City People's Hospital, Zhongshan, Guangdong, China
3 shared publications Xuansheng Huang
Department of Cardiology, Zhongshan City People’ s Hospital, Zhongshan, China
3 shared publications- Bing Hu
Department of Cardiology, Zhongshan City People's Hospital, Zhongshan, Guangdong, China
2 shared publications - Fei Li
Department of Cardiology, Zhongshan City People’s Hospital, 528400 Zhongshan, Guangdong, China
2 shared publications Li Feng
Department of Cardiovascular Medicine, Zhongshan People's Hospital, Sun Yat-sen University
2 shared publications- Tong Liu
Department of Cardiology, Zhongshan City People’s Hospital, 528400 Zhongshan, Guangdong, China
2 shared publications
Latest Publications
- Open Access
- 24 February 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
A predictive model for new-onset mitral regurgitation in ACS patients
Ischemic Mitral Regurgitation (IMR) is a well-established predictor of adverse outcomes following myocardial infarction (MI). Early identification of patie
- 24 February 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Open AccessA predictive model for new-onset mitral regurgitation in ACS patients
Ischemic Mitral Regurgitation (IMR) is a well-established predictor of adverse outcomes following myocardial infarction (MI). Early identification of patie
- Open Access
- 27 January 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13
The role of stress hyperglycemia in in-hospital new-onset atrial fibrillation among patients with acute myocardial infarction: a narrative review
Stress hyperglycemia (SHG) is frequently observed in patients with acute myocardial infarction (AMI). Substantial evidence has established both SHG and the stress hyperglycemia ratio (SHR) as significant, independent predictors of adverse outcomes, linking them to an increased risk of major adverse cardiovascular events and demonstrating a strong association with in-hospital new-onset atrial fibrillation (NOAF). This review consolidates epidemiological evidence linking SHG to these clinical endpoints and details the key underlying pathophysiological mechanisms by which SHG promotes NOAF, including inflammatory activation, oxidative stress activation, calcium handling dysfunction, and autonomic remodeling. Future research should prioritize standardizing diagnostic criteria for SHG, developing integrated dynamic prediction models that incorporate SHG/SHR for NOAF risk, and conducting targeted clinical trials to evaluate early interventions.
- 27 January 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13
Open AccessThe role of stress hyperglycemia in in-hospital new-onset atrial fibrillation among patients with acute myocardial infarction: a narrative review
Stress hyperglycemia (SHG) is frequently observed in patients with acute myocardial infarction (AMI). Substantial evidence has established both SHG and the stress hyperglycemia ratio (SHR) as significant, independent predictors of adverse outcomes, linking them to an increased risk of major adverse cardiovascular events and demonstrating a strong association with in-hospital new-onset atrial fibrillation (NOAF). This review consolidates epidemiological evidence linking SHG to these clinical endpoints and details the key underlying pathophysiological mechanisms by which SHG promotes NOAF, including inflammatory activation, oxidative stress activation, calcium handling dysfunction, and autonomic remodeling. Future research should prioritize standardizing diagnostic criteria for SHG, developing integrated dynamic prediction models that incorporate SHG/SHR for NOAF risk, and conducting targeted clinical trials to evaluate early interventions.
- Open Access
Causal Relationships Between Soluble ST2, Heart Failure, and Sepsis: Bidirectional and Multivariable Mendelian Randomization Analyses
BACKGROUND: Soluble ST2 (sST2) predicts poor outcomes in heart failure (HF) and sepsis, but does it actually drive these conditions or just tag along for the ride? We used bidirectional Mendelian randomization (MR) to find out, testing six directional causal pathways among sST2, HF, and sepsis. METHODS AND RESULTS: Our approach involved bidirectional two-sample Mendelian Randomization(MR) analyses drawing on genome-wide association study (GWAS) summary statistics: sST2 data came from deCODE Genetics (n=30,931), HF data from the Heart Failure Molecular Epidemiology for Therapeutic Targets(HERMES) Consortium (n=977,323), and sepsis data from FinnGen R12 (n=500,348) . We looked at six directions. IVW was the main method, with (Mendelian Randomization–Egger regression)MR-Egger, weighted median, (Mendelian Randomization Pleiotropy RESidual Sum and Outlier)MR-PRESSO sensitivity tests, and multivariable MR (MVMR). We did a cis-SNP analysis too, using only IL1RL1 variants. None of the six pathways showed a causal effect. Genetically predicted sST2 had no link to sepsis (OR: 1.01; 95% CI: 0.94–1.08; P=0.869) or HF (OR: 0.99; 95% CI: 0.92–1.07; P=0.867).cis-SNP analysis gave the same answer for sST2→sepsis (OR: 1.03; 95% CI: 0.98–1.09; P=0.223). MVMR adjusting for HF: still nothing (OR: 1.01; 95% CI: 0.93–1.09; P=0.862). HF and sepsis did not cause each other either - HF→sepsis (OR: 0.98; 95% CI: 0.79–1.23; P=0.882), sepsis→HF (OR: 1.07; 95% CI: 0.96–1.20; P=0.236). Going the other way, genetic risk for HF or sepsis did not affect sST2 levels. CONCLUSIONS: We found no evidence that sST2 causes HF or sepsis. The picture that emerges is one where sST2 goes up because patients are sick-not the other way around. This makes sST2 a useful prognostic signal but probably not something worth targeting with drugs.We also found no direct causal link between HF and sepsis. Clinical Perspective: What Is New?: This bidirectional Mendelian randomization study is the first to comprehensively examine potential causal relationships among soluble ST2, heart failure, and sepsis using genetic instruments. We found no evidence that genetically predicted sST2 levels causally influence the risk of heart failure or sepsis, despite strong observational associations reported in clinical studies. Similarly, genetic liability to heart failure or sepsis does not appear to causally affect circulating sST2 levels, suggesting sST2 elevation is a consequence rather than a cause of these conditions. What Are the Clinical Implications?: These findings suggest that sST2 functions primarily as a prognostic biomarker reflecting disease severity rather than as a driver of pathophysiology, which has implications for its use in clinical decision-making. The strong observational associations between sST2 and adverse cardiovascular outcomes likely reflect confounding or reverse causation rather than direct causal effects. Drug development efforts targeting the ST2/IL-33 signaling pathway should consider that modulating sST2 levels may not directly prevent heart failure or improve sepsis outcomes.
Open AccessCausal Relationships Between Soluble ST2, Heart Failure, and Sepsis: Bidirectional and Multivariable Mendelian Randomization Analyses
BACKGROUND: Soluble ST2 (sST2) predicts poor outcomes in heart failure (HF) and sepsis, but does it actually drive these conditions or just tag along for the ride? We used bidirectional Mendelian randomization (MR) to find out, testing six directional causal pathways among sST2, HF, and sepsis. METHODS AND RESULTS: Our approach involved bidirectional two-sample Mendelian Randomization(MR) analyses drawing on genome-wide association study (GWAS) summary statistics: sST2 data came from deCODE Genetics (n=30,931), HF data from the Heart Failure Molecular Epidemiology for Therapeutic Targets(HERMES) Consortium (n=977,323), and sepsis data from FinnGen R12 (n=500,348) . We looked at six directions. IVW was the main method, with (Mendelian Randomization–Egger regression)MR-Egger, weighted median, (Mendelian Randomization Pleiotropy RESidual Sum and Outlier)MR-PRESSO sensitivity tests, and multivariable MR (MVMR). We did a cis-SNP analysis too, using only IL1RL1 variants. None of the six pathways showed a causal effect. Genetically predicted sST2 had no link to sepsis (OR: 1.01; 95% CI: 0.94–1.08; P=0.869) or HF (OR: 0.99; 95% CI: 0.92–1.07; P=0.867).cis-SNP analysis gave the same answer for sST2→sepsis (OR: 1.03; 95% CI: 0.98–1.09; P=0.223). MVMR adjusting for HF: still nothing (OR: 1.01; 95% CI: 0.93–1.09; P=0.862). HF and sepsis did not cause each other either - HF→sepsis (OR: 0.98; 95% CI: 0.79–1.23; P=0.882), sepsis→HF (OR: 1.07; 95% CI: 0.96–1.20; P=0.236). Going the other way, genetic risk for HF or sepsis did not affect sST2 levels. CONCLUSIONS: We found no evidence that sST2 causes HF or sepsis. The picture that emerges is one where sST2 goes up because patients are sick-not the other way around. This makes sST2 a useful prognostic signal but probably not something worth targeting with drugs.We also found no direct causal link between HF and sepsis. Clinical Perspective: What Is New?: This bidirectional Mendelian randomization study is the first to comprehensively examine potential causal relationships among soluble ST2, heart failure, and sepsis using genetic instruments. We found no evidence that genetically predicted sST2 levels causally influence the risk of heart failure or sepsis, despite strong observational associations reported in clinical studies. Similarly, genetic liability to heart failure or sepsis does not appear to causally affect circulating sST2 levels, suggesting sST2 elevation is a consequence rather than a cause of these conditions. What Are the Clinical Implications?: These findings suggest that sST2 functions primarily as a prognostic biomarker reflecting disease severity rather than as a driver of pathophysiology, which has implications for its use in clinical decision-making. The strong observational associations between sST2 and adverse cardiovascular outcomes likely reflect confounding or reverse causation rather than direct causal effects. Drug development efforts targeting the ST2/IL-33 signaling pathway should consider that modulating sST2 levels may not directly prevent heart failure or improve sepsis outcomes.
- Open Access
- 15 August 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (8) , 37415
Association of Oxidative Balance Score With All-Cause and Cardiovascular Mortality Among Hypertensive Adults
Background: The Oxidative Balance Score (OBS) is a new measure for assessing systemic oxidative stress, where higher scores indicate increased exposure to antioxidants. However, the relationship between the OBS and mortality in individuals with hypertension remains unclear. Methods: This study evaluated 8151 hypertensive individuals from the National Health and Nutrition Examination Survey (NHANES) (2001–2018), utilizing data from the National Death Index, tracked through December 31, 2019. The association between OBS and mortality (cardiovascular and all-cause) was examined using multivariable Cox regression models. Results: During a median follow-up of 9.7 years, which included 1692 deaths (461 of which were cardiovascular), multivariable Cox regression showed the highest quartile of OBS had significantly lower rates of all-cause mortality (hazard ratio (HR) 0.761, 95% CI: 0.635–0.912) and cardiovascular mortality (HR 0.553, 95% CI: 0.388–0.788) compared to those in the lowest quartile. An increase of one unit in the OBS was associated with a 1.9% reduction in all-cause mortality risk and a 3.7% reduction in cardiovascular mortality risk. This relationship remained consistent across various subgroup analyses, and spline regression supported a linear inverse trend. Conclusions: For adults with hypertension, an elevated OBS is independently associated with a lower risk of mortality both from all-cause and cardiovascular diseases, suggesting that higher antioxidant levels may be protective.
- 15 August 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (8) , 37415
Open AccessAssociation of Oxidative Balance Score With All-Cause and Cardiovascular Mortality Among Hypertensive Adults
Background: The Oxidative Balance Score (OBS) is a new measure for assessing systemic oxidative stress, where higher scores indicate increased exposure to antioxidants. However, the relationship between the OBS and mortality in individuals with hypertension remains unclear. Methods: This study evaluated 8151 hypertensive individuals from the National Health and Nutrition Examination Survey (NHANES) (2001–2018), utilizing data from the National Death Index, tracked through December 31, 2019. The association between OBS and mortality (cardiovascular and all-cause) was examined using multivariable Cox regression models. Results: During a median follow-up of 9.7 years, which included 1692 deaths (461 of which were cardiovascular), multivariable Cox regression showed the highest quartile of OBS had significantly lower rates of all-cause mortality (hazard ratio (HR) 0.761, 95% CI: 0.635–0.912) and cardiovascular mortality (HR 0.553, 95% CI: 0.388–0.788) compared to those in the lowest quartile. An increase of one unit in the OBS was associated with a 1.9% reduction in all-cause mortality risk and a 3.7% reduction in cardiovascular mortality risk. This relationship remained consistent across various subgroup analyses, and spline regression supported a linear inverse trend. Conclusions: For adults with hypertension, an elevated OBS is independently associated with a lower risk of mortality both from all-cause and cardiovascular diseases, suggesting that higher antioxidant levels may be protective.
- Open Access
- 19 May 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (4) , 2985-2992
The Effects of Early Exercise on Cardiovascular Biomarkers in Patients witH Congestive Heart Failure
Background: Exercise training improves functional outcomes in chronic heart failure (HF), but the effects of early in-hospital physical activity on cardiovascular biomarkers and prognosis in acute congestive heart failure (AHF) patients remain unclear. This study investigated the short-term impact of early rehabilitation on prognostic biomarkers—high-sensitivity troponin T (hs-TnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), soluble suppression of tumourigenesis-2 (sST2), galectin-3 (Gal-3) and endothelin-1 (ET-1)—and evaluated associations with clinical outcomes. Methods and results: A total of 118 hospitalized AHF patients (35 controls and 83 exercise group) underwent biomarker measurement before and after supervised rehabilitation using non-invasive cardiac output monitoring. Serum levels of NT-proBNP, hs-TnT, sST2, Gal-3, and ET-1 were analysed. Prognosis was assessed via 12-month follow-up for all-cause mortality. Statistical analysis included ANOVA for biomarker changes and Kaplan–Meier survival analysis. Post-intervention, NT-proBNP levels increased significantly in the exercise group (2900 ± 700 pg/mL to 3500 ± 760 pg/mL, P = 0.012), as did ET-1 (1.9 ± 0.4 pg/mL to 2.4 ± 0.5 pg/mL, P = 0.018). Hs-TnT, sST2 and Gal-3 showed no significant changes (all P > 0.05). Survival analysis demonstrated higher baseline hs-TnT [hazard ratio (HR) 2.1, 95% confidence interval (CI) 1.3–3.4] and greater NT-proBNP elevation post-exercise (ΔNT-proBNP HR 1.8, 95% CI 1.1–2.9) were independent predictors of mortality. Conclusions: Early in-hospital exercise in AHF patients transiently elevates NT-proBNP and ET-1, indicative of acute haemodynamic stress, without altering myocardial injury or fibrosis markers (hs-TnT, sST2 and Gal-3). Elevated baseline hs-TnT and post-exercise NT-proBNP increases correlate with poorer survival, highlighting their prognostic value in risk assessment.
- 19 May 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (4) , 2985-2992
Open AccessThe Effects of Early Exercise on Cardiovascular Biomarkers in Patients witH Congestive Heart Failure
Background: Exercise training improves functional outcomes in chronic heart failure (HF), but the effects of early in-hospital physical activity on cardiovascular biomarkers and prognosis in acute congestive heart failure (AHF) patients remain unclear. This study investigated the short-term impact of early rehabilitation on prognostic biomarkers—high-sensitivity troponin T (hs-TnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), soluble suppression of tumourigenesis-2 (sST2), galectin-3 (Gal-3) and endothelin-1 (ET-1)—and evaluated associations with clinical outcomes. Methods and results: A total of 118 hospitalized AHF patients (35 controls and 83 exercise group) underwent biomarker measurement before and after supervised rehabilitation using non-invasive cardiac output monitoring. Serum levels of NT-proBNP, hs-TnT, sST2, Gal-3, and ET-1 were analysed. Prognosis was assessed via 12-month follow-up for all-cause mortality. Statistical analysis included ANOVA for biomarker changes and Kaplan–Meier survival analysis. Post-intervention, NT-proBNP levels increased significantly in the exercise group (2900 ± 700 pg/mL to 3500 ± 760 pg/mL, P = 0.012), as did ET-1 (1.9 ± 0.4 pg/mL to 2.4 ± 0.5 pg/mL, P = 0.018). Hs-TnT, sST2 and Gal-3 showed no significant changes (all P > 0.05). Survival analysis demonstrated higher baseline hs-TnT [hazard ratio (HR) 2.1, 95% confidence interval (CI) 1.3–3.4] and greater NT-proBNP elevation post-exercise (ΔNT-proBNP HR 1.8, 95% CI 1.1–2.9) were independent predictors of mortality. Conclusions: Early in-hospital exercise in AHF patients transiently elevates NT-proBNP and ET-1, indicative of acute haemodynamic stress, without altering myocardial injury or fibrosis markers (hs-TnT, sST2 and Gal-3). Elevated baseline hs-TnT and post-exercise NT-proBNP increases correlate with poorer survival, highlighting their prognostic value in risk assessment.
- Open Access
- 12 February 2025
- Published by Walter de Gruyter GmbH in Oncologie
- Vol. 27 (2) , 295-305
Prognostic implications of PCSK9 expression in HER2-positive breast cancer
Objectives: PCSK9 is critical in cholesterol homeostasis and anti-tumor immunity modulation. This study aims to investigate PCSK9’s role in HER2-positive breast cancer (BC) as a potential prognostic marker. Methods: The impact of PCSK9 on HER2-positive BC was analyzed by virtue of data from The Cancer Genome Atlas (TCGA). Moreover, PCSK9 expression in tumor cells from 92 HER2-positive patients was assessed through immunohistochemistry (IHC). Then, it was found that this expression was correlated with various clinicopathological parameters including histological grading, hormone receptor (HR) status, and patient survival. Results: PCSK9 expression positively correlated with pathohistological grading and hormone receptor status, but negatively with patient survival. GSEA showed low PCSK9 expression groups enriched in immune-related pathways, while high expression groups favored coagulation pathways. CIBERSORT analysis revealed a notable negative association between PCSK9 expression and γδ T cells, suggesting PCSK9’s role in modulating tumor microenvironment (TME) immune reactivity. Low PCSK9 expression was associated with a more favorable response to neoadjuvant therapy in patients. Conclusions: PCSK9 expression in HER2-positive BC is a significant prognostic indicator, with higher levels related to worse clinical outcomes. These results suggest PCSK9’s potential utility in predicting treatment responses and guiding therapeutic strategies for HER2-positive BC patients.
- 12 February 2025
- Published by Walter de Gruyter GmbH in Oncologie
- Vol. 27 (2) , 295-305
Open AccessPrognostic implications of PCSK9 expression in HER2-positive breast cancer
Objectives: PCSK9 is critical in cholesterol homeostasis and anti-tumor immunity modulation. This study aims to investigate PCSK9’s role in HER2-positive breast cancer (BC) as a potential prognostic marker. Methods: The impact of PCSK9 on HER2-positive BC was analyzed by virtue of data from The Cancer Genome Atlas (TCGA). Moreover, PCSK9 expression in tumor cells from 92 HER2-positive patients was assessed through immunohistochemistry (IHC). Then, it was found that this expression was correlated with various clinicopathological parameters including histological grading, hormone receptor (HR) status, and patient survival. Results: PCSK9 expression positively correlated with pathohistological grading and hormone receptor status, but negatively with patient survival. GSEA showed low PCSK9 expression groups enriched in immune-related pathways, while high expression groups favored coagulation pathways. CIBERSORT analysis revealed a notable negative association between PCSK9 expression and γδ T cells, suggesting PCSK9’s role in modulating tumor microenvironment (TME) immune reactivity. Low PCSK9 expression was associated with a more favorable response to neoadjuvant therapy in patients. Conclusions: PCSK9 expression in HER2-positive BC is a significant prognostic indicator, with higher levels related to worse clinical outcomes. These results suggest PCSK9’s potential utility in predicting treatment responses and guiding therapeutic strategies for HER2-positive BC patients.
- 30 March 2022
- Published by International Heart Journal (Japanese Heart Journal) in International Heart Journal
- Vol. 63 (2) , 416-420
A Case of Syncope in a Child due to the Large Segment of Myocardial Bridge
We report a child with an unusual coronary bridge crossing over the left anterior descending (LAD), circumflex (CX), and right coronary artery (RCA). The bridges range from 0.8-1.2 mm depth. The patient presented with exercise-induced syncope and myocardial infarction (MI). She exhibited no syncope after medicine and exercise control.
- 30 March 2022
- Published by International Heart Journal (Japanese Heart Journal) in International Heart Journal
- Vol. 63 (2) , 416-420
A Case of Syncope in a Child due to the Large Segment of Myocardial Bridge
We report a child with an unusual coronary bridge crossing over the left anterior descending (LAD), circumflex (CX), and right coronary artery (RCA). The bridges range from 0.8-1.2 mm depth. The patient presented with exercise-induced syncope and myocardial infarction (MI). She exhibited no syncope after medicine and exercise control.
- Open Access
- 8 December 2013
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 12 (1) , 180
The combination of L-4F and simvastatin stimulate cholesterol efflux and related proteins expressions to reduce atherosclerotic lesions in apoE knockout mice
Both L-4F, one apolipoprotein A-1 mimetic peptide, and statins can reduce progression of atherosclerosis by different mechanisms. The combination of the two drugs can cause lesion regression by rendering HDL anti-inflammatory. We postulated that combination of L-4F and simvastatin may stimulate cholesterol efflux and related proteins expressions to alleviate atherosclerosis. Thirty male wild-type (W-T) C57 BL/6 mice and apo E−/− mice were divided into five groups: W-T group, atherosclerosis (AS) group, simvastatin group, L-4F group and the combination of simvastatin and L-4F group. After 16 weeks, serum lipids, atherosclerotic lesion areas, cholesterol efflux and the expressions of related proteins including ABCA1, SR-BI, ABCG1, LXRα and PPARγ were evaluated. The aortic atherosclerotic lesion areas were reduced more significantly by combination of both drugs than single agent, and cholesterol efflux was promoted more in combination group than simvastatin and L-4F group. Besides, the combination group promoted expressions of cholesterol efflux related proteins. The combination of L-4F and simvastatin reduced atherosclerotic lesions, which stimulates cholesterol efflux by promoting the expressions of related proteins. In addition, these results help us further understand that the regression of the atherosclerosis would be assessed by reduction in LDL-C with increase of cholesterol efflux.
- 8 December 2013
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 12 (1) , 180
Open AccessThe combination of L-4F and simvastatin stimulate cholesterol efflux and related proteins expressions to reduce atherosclerotic lesions in apoE knockout mice
Both L-4F, one apolipoprotein A-1 mimetic peptide, and statins can reduce progression of atherosclerosis by different mechanisms. The combination of the two drugs can cause lesion regression by rendering HDL anti-inflammatory. We postulated that combination of L-4F and simvastatin may stimulate cholesterol efflux and related proteins expressions to alleviate atherosclerosis. Thirty male wild-type (W-T) C57 BL/6 mice and apo E−/− mice were divided into five groups: W-T group, atherosclerosis (AS) group, simvastatin group, L-4F group and the combination of simvastatin and L-4F group. After 16 weeks, serum lipids, atherosclerotic lesion areas, cholesterol efflux and the expressions of related proteins including ABCA1, SR-BI, ABCG1, LXRα and PPARγ were evaluated. The aortic atherosclerotic lesion areas were reduced more significantly by combination of both drugs than single agent, and cholesterol efflux was promoted more in combination group than simvastatin and L-4F group. Besides, the combination group promoted expressions of cholesterol efflux related proteins. The combination of L-4F and simvastatin reduced atherosclerotic lesions, which stimulates cholesterol efflux by promoting the expressions of related proteins. In addition, these results help us further understand that the regression of the atherosclerosis would be assessed by reduction in LDL-C with increase of cholesterol efflux.
- 15 October 2013
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 8 (1) , 21-27
Influence of autoantibodies against AT1 receptor and AGTR1 polymorphisms on candesartan-based antihypertensive regimen
- 15 October 2013
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 8 (1) , 21-27
Influence of autoantibodies against AT1 receptor and AGTR1 polymorphisms on candesartan-based antihypertensive regimen